Vaishali Pharma Limited — Important, 19-02-2025: Agreements

The Board of Directors of Vaishali Pharma Limited has approved a Share Subscription Agreement to acquire a 51.02% stake in Kesar Pharma Limited by subscribing to 35,89,201 equity shares at a total investment of ₹20.41 Cr. This will be executed in multiple tranches, with ₹8.17 Cr paid in cash and the remaining ₹12.24 Cr settled through the issuance of fresh equity shares.

Kesar Pharma, founded in 2011, specializes in manufacturing and developing pharmaceutical formulations. Its revenue for the financial year ending March 31, 2024, was ₹27.26 Cr. This acquisition aligns with Vaishali Pharma’s strategy to expand into new healthcare product lines, leveraging its distribution network for enhanced market positioning. Kesar Pharma will become a subsidiary post-acquisition, which is expected to complete by February 19, 2026, subject to certain approvals. This move indicates a positive outlook for the company’s growth trajectory and operational capabilities in the evolving healthcare sector.